Edap Tms (NASDAQ:EDAP) Posts Quarterly Earnings Results, Misses Estimates By $0.10 EPS

Edap Tms (NASDAQ:EDAP) issued its quarterly earnings data on Wednesday. The medical equipment provider reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.10), FiscalAI reports. Edap Tms had a negative return on equity of 61.60% and a negative net margin of 30.95%.The business had revenue of $22.22 million during the quarter, compared to the consensus estimate of $21.28 million.

Edap Tms Trading Up 4.8%

Edap Tms stock opened at $3.91 on Wednesday. Edap Tms has a 12-month low of $1.21 and a 12-month high of $5.05. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.41 and a quick ratio of 0.97. The stock has a market capitalization of $146.19 million, a PE ratio of -6.86 and a beta of -0.19. The firm has a 50 day simple moving average of $4.23 and a 200-day simple moving average of $3.14.

Hedge Funds Weigh In On Edap Tms

An institutional investor recently raised its position in Edap Tms stock. Rock Springs Capital Management LP grew its holdings in shares of Edap Tms S.A. (NASDAQ:EDAP) by 1.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,286,500 shares of the medical equipment provider’s stock after purchasing an additional 16,500 shares during the period. Rock Springs Capital Management LP owned approximately 3.44% of Edap Tms worth $4,233,000 as of its most recent filing with the Securities and Exchange Commission. 62.74% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have weighed in on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Edap Tms in a research note on Monday, December 29th. Wall Street Zen raised Edap Tms to a “hold” rating in a report on Saturday, February 7th. One research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Edap Tms presently has an average rating of “Hold” and an average price target of $8.50.

Edap Tms Company Profile

Edap Tms SA (NASDAQ: EDAP) is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm’s core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms’s Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.